Novel oral GLP-1 confers glucose, weight reduction

Дата публикации: 23-06-2026 12:57:12

NEW ORLEANS — A novel oral small-molecule GLP-1 receptor agonist demonstrated reductions in HbA1c and body weight among individuals with type 2 diabetes and obesity.Researchers presented results from the phase 2 SOLSTICE and VISTA studies at the American Diabetes Association Scientific Sessions. Both studies evaluated efficacy, safety and tolerability of elecoglipron (AstraZeneca); SOLSTICE included adults with type 2 diabetes and inadequate glycemic control and VISTA included adults with obesity or overweight plus at least one weight-related comorbidity.Elecoglipron is an oral

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Foundayo bests Farxiga and Ozempic pill in type 2 diabetes trials	0	8	19-06-2026
2	Semaglutide may reduce fracture risk in type 2 diabetes	0	5	24-06-2026
3	GLP-1 RAs do not improve migraines	0	6	19-06-2026
4	Stanford researchers say your body already makes this Ozempic alternative	0	7	15-06-2026
5	Got ‘Ozempic Butt’? Fix Your Flat And Flabby Booty With Experimental New Drug	0	0	18-06-2026
6	Women over 50 lost 35% more weight with this surprising combo	2	7	24-03-2026
7	The 'biohacking' trend that has tech workers experimenting on themselves	0	6	19-01-2026
8	One 79-year-old patient was granted access to unapproved powerful obesity drug	0	0	23-06-2026
9	What to know about the temporary Medicare GLP-1 Bridge program	0	0	21-06-2026
10	White House forced to deny Trump was lone patient to get experimental obesity drug	0	0	23-06-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 5. Информативность: 7. Источник: www.healio.com.